Phase 1, open-label study of BHV-0223 in ALS.
This is a phase 1, open-label, single arm study to evaluate the safety, tolerability and pharmacokinetics of multiple doses of BHV-0223 in subjects with ALS.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
22
BHV-0223, 40 mg BID
Holy Cross Neuroscience Research Institute
Fort Lauderdale, Florida, United States
Somnos/Neurology Associates Clinical Research
Lincoln, Nebraska, United States
Neurosciences Institute, Neurology - Charlotte
Charlotte, North Carolina, United States
Wesley Neurology Clinic
Cordova, Tennessee, United States
Incidence of Treatment Emergent Adverse Events (Safety and Tolerability)
Incidence of treatment emergent adverse events (safety and tolerability) as measured through laboratory tests and physical exam findings.
Time frame: Through Week 8 (Day 57)
BHV-0223 Concentrations in Blood at Days 1, 29 and 57
BHV-0223 concentrations at days 1, 29 and 57 through blood collections at days 1, 29 and 57.
Time frame: Through Week 8 (Day 57)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Texas Neurology
Dallas, Texas, United States